ZYBERNO
Stock Report
Updated Sep 1, 2026

NeuroOne Medical Technologies Corporation (NMTC)

Healthcare • NASDAQ

$1.70

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
27.0/100
POOR BUSINESS
NeuroOne Medical Technologies Corporation (NMTC) scores 27/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-131.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.09x)
Operating Margin (Operational Efficiency):CRITICAL (-83.4%)
Return on Capital (Capital Efficiency):CRITICAL (-312.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

NeuroOne Medical Technologies Corporation (NMTC) stock report — Zyberno Score 27/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.70
Market Cap:$14.72M

Valuation Multiples (3)

P/B Ratio:3.91x
P/S Ratio:1.56x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$12.85M

Price Action & Momentum (3)

Momentum Percentile:19 / 100
% of 52-Week High:24.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-89.1%
Reinvestment Rate:3.0%
Fundamental Growth Rate (g):-9.5%

Margin Analysis (3)

Operating Margin Ttm:-83.4%
Net Margin Ttm:-78.6%
Ebitda Margin:-80.6%

TTM Performance (3)

Gross Margin Ttm:55.6%
Operating Margin Ttm:-83.4%
Net Margin Ttm:-78.6%

Yield Metrics (2)

Earnings Yield:-$32.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-22,500.0%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.84x
Quick Ratio:1.71x
Cash Ratio:1.00x

Leverage Analysis (3)

Debt To Equity Ttm:0.09x
Debt-to-Equity Ratio:0.09x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:3,747,374.00
Cash And Cash Equivalents:2,047,596.00
Long Term Debt:$73.32K
Net Debt:-$1.87M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $9.47M
Linear Growth: 100.0%
📊 Click to view full NMTC Revenue analysis & methodology →
Cost Of Revenue Ttm:$4.20M

Profitability Breakdown (2)

Gross profit TTM: $5.27M
Linear Growth: 100.0%
📊 Click to view full NMTC Gross Profit analysis & methodology →
-$7.90M

Bottom Line Performance (3)

-$7.45M
Income Before Tax:-$7.45M
Ebitda Ttm:-7,629,529.00

Operating Expenses (5)

Operating Expenses:13,169,202.00
R And D Expense:5,400,909.00
Sga Expense:7,768,293.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:273.7%
Sga To Revenue Percentage:393.7%
Ebitda Margin:-80.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.19M
Current Assets:$5.79M
Ppe Net:1,156,974.00
Goodwill:0.00
Intangible Assets:$28.21K

Liability Structure (4)

Total Liabilities:2,418,552.00
Current Liabilities:2,041,427.00
Long Term Debt:$73.32K
Short Term Debt:$102.03K

Equity & Capital (3)

Equity:$3.77M
Retained Earnings:-$84.44M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:1,098,965.00
Inventory:2,290,254.00
Accounts Payable:905,716.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:352,777.00
C. Cash Flow Analysis

Operating Activities (2)

-$6.16M-$2.92M

Investment Activities (1)

Investing Cash Flow:-$40.75K

Financing Activities (3)

Financing Cash Flow:$147.82K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:5,033,906.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:270,351.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.59
-$0.64
Earnings Per Share Ttm:-$0.86

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.09
Operating Cash Flow Per Share:-$0.33

Book Value & Capital (2)

Book Value Per Share:$0.43
Cash Per Share:0.24

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.13x
Working Capital Turnover Ttm:2.53x

Receivables Management (2)

Receivables Turnover Ttm:8.62x
Days Sales Outstanding Ttm:42.36

Inventory Management (2)

Inventory Turnover Ttm:1.83x
Days Inventory Outstanding Ttm:199.06

Payables & Cash Cycle (2)

Days Payable Outstanding:78.72
Cash Conversion Cycle:162.70
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:3.0%
Fundamental Growth Rate (g):-9.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):100.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):100.0%
Book Value Growth Rate (Linear):-17.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:NMTC
Company Name:NeuroOne Medical Technologies Corporation
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:8.66M
Shares Outstanding Basic:8.66M
Shares Outstanding Diluted:8.74M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 08:27:04 UTC
Data Timestamp:2026-08-20T21:29:34.371403
Scroll to Top